A Single Non‐Invasive Test Cut‐Off Should Not Serve Three Distinct Clinical Purposes in Metabolic Dysfunction‐Associated Steatotic Liver Disease and Steatohepatitis

Documenti analoghi

• Cardiovascular Disease Risk Prediction in Patients With Metabolic Dysfunction‐Associated Steatohepatitis
  di: Joe Hollinghurst, et al.
  Pubblicazione: (2026)
• Serum IGF ‐1 and the Risk of Cardio‐Kidney Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease
  di: Yongin Cho, et al.
  Pubblicazione: (2026)
• Obesity and Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ): A Literature Review on Pathophysiology and Treatment
  di: Michael Romanos, et al.
  Pubblicazione: (2026)
• High Prevalence of Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics
  di: Srilaxmi Kalavalapalli, et al.
  Pubblicazione: (2026)
• Sexually Dimorphic Impacts of Early Life BCAAs Supplementation on Metabolic Dysfunctions in Adult Mice
  di: Qianqian Yue, et al.
  Pubblicazione: (2026)